AbbVie announces first regulatory approval of Skyrizi (risankizumab) for the treatment of plaque psoriasis, generalised pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan

AbbVie

26 March 2019 - This marks the first regulatory approval globally for SKYRIZI™ (risankizumab).

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has approved Skyrizi (risankizumab), an interleukin-23 inhibitor, for the treatment of plaque psoriasis, generalised pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.

"With this first global approval of Skyrizi, we are excited to bring a new treatment option to people living with psoriatic disease in Japan," said Michael Severino, M.D., vice chairman and president, AbbVie. "Skyrizi has the potential to improve the signs and symptoms of these chronic, immune-mediated diseases. We look forward to continuing to work with regulatory authorities to make this treatment available to more patients worldwide."

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Japan